Share
The mRNA-1273.222 vaccine acts on the original SARS-CoV-2 viral strain and the BA.4/BA.5 strains. Credit: Eric Garcetti / Flickr (Creative Commons).

The European Medicines Agency (EMA) has accepted Moderna’s submission seeking a variation to the Conditional Marketing Authorization (CMA) for assessing a 50µg dose of the Omicron-based bivalent Covid-19 booster candidate, mRNA-1273.222, for adults aged 12 years and above. 

The mRNA-1273.222 vaccine comprises 25µg doses of mRNA-1273 (Spikevax) and a vaccine candidate against the BA.4/BA.5 subvariants of Omicron.

Related Company Profiles

View all

It acts on the original SARS-CoV-2 viral strain and the BA.4/BA.5 strains. 

Moderna filed the application based on preclinical findings for mRNA-1273.222 and results from the Phase II/III clinical trial of a bivalent booster shot targeting the Omicron BA.1 subvariant, mRNA-1273.214.

The latest submission comes after the company received approval for mRNA-1273.214 this month.

Moderna has so far obtained authorisations for Omicron-targeting bivalent booster vaccine in the US, Canada, Europe, Australia, South Korea, Switzerland, Japan, Singapore, Taiwan and the UK.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is also seeking regulatory approvals across the globe.

Moderna CEO Stéphane Bancel said: “We are proud to announce this filing for the use of our bivalent Covid-19 vaccine targeting the BA.4/BA.5 Omicron subvariants in the European Union.

“Following the recent approval of our BA.1 targeting vaccine in Europe, our BA.4/BA5 Omicron targeting vaccine will now bring a second option to help protect people across Europe as we head into the winter months.”

In August, the company filed patent infringement lawsuits against Pfizer and BioNTech in the US District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany over messenger ribonucleic acid (mRNA) technology.

Comirnaty, the Covid-19 vaccine of Pfizer and BioNTech, is said to have infringed patents filed by Moderna between 2010 and 2016 for this technology.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.